Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481899 | 1.00 | TLR8 (0.43) | TLR8DPP4DPP8DPP9CRHR1 | |
| SCHEMBL1481743 | 0.97 | TLR8 (0.43) | TLR8DPP4DPP8DPP9CRHR1 | |
| SCHEMBL1481741 | 0.97 | TLR8 (0.43) | TLR8DPP4DPP8DPP9CRHR1 | |
| SCHEMBL1480852 | 0.94 | DPP4 (0.42) | TLR8DPP4DPP8DPP9CRHR1 | |
| SCHEMBL1480849 | 0.94 | DPP4 (0.42) | TLR8DPP4DPP8DPP9CRHR1 | |
| SCHEMBL1480190 | 0.90 | DPP4 (0.43) | DPP4DPP8DPP9ALDH1A1LMNA | |
| SCHEMBL1480187 | 0.90 | DPP4 (0.43) | DPP4DPP8DPP9ALDH1A1LMNA | |
| SCHEMBL1480970 | 0.89 | TLR8 (0.42) | TLR8DPP4LMNAMAPT | |
| SCHEMBL1481407 | 0.89 | ATP4A (0.45) | TLR8LMNAMAPTAHRCNR1 | |
| SCHEMBL1481410 | 0.89 | ATP4A (0.45) | TLR8LMNAMAPTAHRCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-1594847-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004071447-A9 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | TLR8 2695/4885DPP4 132/4885DPP8 144/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | TLR8 2695/4885DPP4 132/4885DPP8 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.